Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer
2期
进行中（已停止招募）
NCT02893917
| 适应症 | Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Carcinoma |
|---|
| 分期 | 2期 |
|---|
| 申办方 | National Cancer Institute (NCI) |
|---|
| 状态 | 进行中（已停止招募） |
|---|
| 受试者人数 | 90 人 |
|---|
| 干预（药物） | Cediranib, Olaparib |
|---|
| 开始日期 | 2017年8月11日 |
|---|
| 完成日期 | 2023年3月14日 |
|---|
| 结果公布日 | 2025年3月30日 |
|---|
摘要
This randomized phase II trial studies how well olaparib with or without cediranib works in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Cediranib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving olaparib and cediranib may help treat patients with castration-resistant prostate cancer.
Radiographic Progression Free Survival
Time interval from random assignment to the date when the first site of disease is found to progress, or death, whichever occurs first, assessed up to 5 years · months
| Arm A (Olaparib, Cediranib) | 8.5 months |
|---|
| Arm B (Olaparib) | 4.0 months |
|---|
| p-value | 0.0359 |
|---|
| Hazard Ratio (HR) | 0.617 (95% CI 0.392–0.969) |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
同一适应症的其他试验
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。